Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Phathom Pharmaceuticals (PHAT) over the last 6 years, with Dec 2024 value amounting to -$135,000.

  • Phathom Pharmaceuticals' Cash from Investing Activities rose 38.64% to -$27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$147,000, marking a year-over-year increase of 75.70%. This contributed to the annual value of -$135,000 for FY2024, which is 91.74% up from last year.
  • Phathom Pharmaceuticals' Cash from Investing Activities amounted to -$135,000 in FY2024, which was up 91.74% from -$1.6 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' Cash from Investing Activities ranged from a high of -$135,000 in FY2024 and a low of -$1.6 million during FY2023.
  • Its 3-year average for Cash from Investing Activities is -$936,667, with a median of -$1.0 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 95.88% in 2020, then plummeted by 217.38% in 2022.
  • Phathom Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$1.0 million in 2020, then soared by 68.46% to -$328,000 in 2021, then plummeted by 217.38% to -$1.0 million in 2022, then tumbled by 56.96% to -$1.6 million in 2023, then surged by 91.74% to -$135,000 in 2024.